Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
UNIVERSITAET ZUERICH currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, NEGIN, RUSSELL SCOTT, who is the busiest examiner with 1 pending application. The portfolio is active in 1 distinct art unit, indicating a streamlined prosecution process for the company's current filings.
This 1 to 1 ratio of pending office actions to examiners indicates that the company's immediate workload is concentrated. Since NEGIN, RUSSELL SCOTT is the 1 distinct examiner currently reviewing the company's work, the prosecution success relies on meeting the specific criteria of this official. Practitioners should focus on the 1 pending office action as the sole driver of the company's current interactions with the patent office.
The focus on 1 distinct art unit within the Biotechnology & Pharmaceuticals sector suggests a specialized technical niche. Successfully addressing the 1 pending application under NEGIN, RUSSELL SCOTT will be the primary objective for the company's current patent strategy. This focused administrative environment allows the company to dedicate significant attention to the feedback provided in the 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NEGIN, RUSSELL SCOTT | 1 | 55.9% | +34.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17641247 | Method for Evaluating Damage of Solid Tissue | NEGIN, RUSSELL SCOTT | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17641247 | Method for Evaluating Damage of Solid Tissue | NEGIN, RUSSELL SCOTT | — |
| Art Unit | Apps |
|---|---|
| 1686 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17641247 | Method for Evaluating Damage of Solid Tissue | NEGIN, RUSSELL SCOTT | 1686 | §101§103§112 | Final Rejection | — | Pending | Mar 08, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUNIVERSITAET ZUERICH has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Russell Scott Negin has the most, with 1 of UNIVERSITAET ZUERICH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
